跳到主要內容
Quest Diagnostics Home.

創建腎髒健康的完整畫麵

Chronic kidney disease (CKD) affects 37 million people in the U.S., but most of them are undiagnosed: 9 in 10 adults with CKD don’t know they have it.1 These missed diagnoses drive hospitalizations and costs,2 and risk bad outcomes.
\r\n

\r\n

Quest Diagnostics provides the complete testing and expert guidance you need to diagnose CKD, manage progression, establish follow-ups, and initiate nephrology referrals. With combined insights from eGFR, uACR, and other panels, you can feel empowered to get a complete picture of your patient’s kidney health.

\r\n"}}" id="text-749a79dcea" class="cmp-text">

慢性腎病(CKD)在美國影響了3700萬人,但大多數人都未知道:9人中有9個成年人,CKD不知道他們擁有它。1這些錯過診斷了駕駛住院和成本,2和風險不良結果。

Quest Diagnostics提供了診斷CKD,管理進展,建立隨訪和啟動腎病的完整測試和專家指導。隨著EGFR,UACR等組合的洞察力,您可以感到有權了解患者患者的腎髒健康。

治療潛在的原因可以改善患者的結果

In the early stages of CKD, patients may not have many signs or symptoms, impacting the diagnosis and management of the disease. CKD may not become apparent until kidney function is significantly impaired. However, there are certain signs that people with diabetes may be developing CKD that can help with detection and treatment:

\r\n
    \r\n
  • Protein in the urine
  • \r\n
  • High blood pressure
  • \r\n
  • Leg swelling or cramps
  • \r\n
  • Increased need to urinate, especially at night
  • \r\n
  • Abnormal blood tests (glomerular filtration rate, GFR)
  • \r\n
  • Less need for insulin or anti-diabetic agents
  • \r\n
  • Nausea and vomiting
  • \r\n
  • Weakness
  • \r\n
  • Pallor and anemia
  • \r\n
\r\n

Controlling the underlying cause of CKD—such as diabetes—can slow the progression of kidney damage that can lead to end-stage renal disease. 

\r\n"}}" id="text-765574dc27" class="cmp-text">

在CKD的早期階段,患者可能沒有許多跡象或症狀,影響疾病的診斷和管理。直到腎功能顯然受損,CKD可能不會變得明顯。但是,有一些患有糖尿病的跡象可能正在開發CKD,可以有助於檢測和治療:

  • 尿液中的蛋白質
  • 高血壓
  • 腿部腫脹或痙攣
  • 增加需要小便,特別是在晚上
  • 異常血液檢測(腎小球過濾速率,GFR)
  • 對胰島素或抗糖尿病藥劑的需求較​​少
  • 惡心和嘔吐
  • 弱點
  • Pallor和貧血

控製CKD的潛在原因 - 例如糖尿病 - 可以減緩腎髒損傷的進展,這可能導致腎病腎病。

定義慢性病條件:一種預防的心肌疾病方法

With more people at risk for cardiovascular disease than ever before, the Quest Cardiometabolic Center of Excellence™ at Cleveland HeartLab® is advancing a prevention-focused approach for heart disease and associated metabolic conditions.

\r\n
    \r\n
  • Cardiovascular disease is the leading cause of death for individuals who have T2DM,4 stage 4-5 CKD,5 and NAFLD.6
  • \r\n
  • Those who have T2DM have a 2 to 3 times higher risk of fatal coronary heart disease.7
  • \r\n
  • Nearly 40% of persons who have diabetes and more than 30% of those who have hypertension also have CKD.8 The leading causes of end-stage renal disease are diabetes and hypertension.9
  • \r\n
  • More than 75% of those who have T2DM have NAFLD.10
  • \r\n
\r\n

Cardiovascular disease (CVD) is strongly associated with type 2 diabetes (T2DM), chronic kidney disease (CKD), and nonalcoholic fatty liver disease (NAFLD). Through significant investments in novel technology, the Cleveland HeartLab® is fostering innovation to detect these conditions in their early stages, providing the opportunity for stage-targeted intervention and improved clinical outcomes.
\r\n

\r\n"}}" id="text-5e38180e0c" class="cmp-text">

憑借以前比以往任何時候都有更多人心血管疾病風險,Quest Cardifometabolic卓越中心在克利夫蘭Heartlab®中推進了一種預防心髒病和相關的代謝條件的方法。

  • 心血管疾病是具有T2DM的個人死亡的主要原因,4.階段4-5 CKD,5.和nafld。6.
  • 那些具有T2DM的人具有致命冠心病風險較高的2%至3倍。7.
  • 近40%的患有糖尿病和超過30%的高血壓的人也有CKD。8.末期腎病的主要原因是糖尿病和高血壓。9.
  • 超過75%的人有T2DM有NAFLD。10.

心血管疾病(CVD)與2型糖尿病(T2DM),慢性腎病(CKD)和非酒精性脂肪肝病(NAFLD)強烈相關。通過對新技術的重大投資,克利夫蘭Heartlab®正在促進創新,以檢測其早期階段的這些條件,為階段目標幹預提供機會和改善的臨床結果。


慢性腎病試驗

評估腎功能和危險患者的腎功能和腎髒障礙

Traditional serum creatinine (eGFR) testing may only reveal one side of the CKD story. For a more complete picture, guidelines recommend both the eGFR blood test and the urine albumin-to-creatinine ratio (uACR) test to assess kidney function and damage.11 This combination enables early detection, essential to managing CKD progression.
\r\n

\r\n

The Kidney Profile from Quest includes both tests, enabling earlier detection with just one test code. Quest offers the guideline-based testing you need to help diagnose CKD, manage disease progression, and establish follow-up testing frequency. You’ll also know when a referral to a nephrologist is recommended.

\r\n

Learn more about the Kidney Profile test

\r\n"}}" id="text-10b7038bed" class="cmp-text">

傳統的血清肌酐(EGFR)測試可能隻會揭示CKD故事的一側。對於更完整的圖片,指南建議EGFR血液測試和尿白黴素至肌酐比(UACR)測試,以評估腎功能和損傷。11.這種組合能夠提前檢測,對管理CKD進展至關重要。

Quest的腎功能介紹包括兩個測試,隻需一個測試代碼就可以先檢測到。任務提供了基於指導的測試,您需要幫助診斷CKD,管理疾病進展,並建立跟進測試頻率。您還會知道推薦給腎病學家的轉診。

了解有關腎功能測試的更多信息

It can be challenging to adhere to guidelines-based testing for patients who have progressed to stage 3 or 4 CKD—extensive work-up is required for these high-risk cases. However, consolidating all diagnostics within a single test code can help you meet guidelines from both the National Kidney Foundation12 and American Diabetes Association13 for monitoring and managing renal status.

\r\n

Quest Diagnostics enables a straightforward approach with our comprehensive panel for advanced CKD management. Designed to be used annually in all patients with stage 3 or 4 CKD, the single-code panel assesses:
\r\n

\r\n
    \r\n
  • Fasting lipid levels
  • \r\n
  • Fasting glucose
  • \r\n
  • HbA1c
  • \r\n
  • Liver functions (albumin, total and direct bilirubin, alkaline phosphatase, total protein, ALT, AST)
  • \r\n
  • Urinary albumin excretion (UAE)
  • \r\n
  • Serum creatinine/eGFR
  • \r\n
\r\n

Learn more about the Diabetes and Advancing CKD Management Panel

\r\n"}}" id="text-df65002a3d" class="cmp-text">

對於這些高風險案件所需,遵守基於準則的患者可能具有挑戰性,遵守基於指南的基於準則的患者,這是對3階段的患者進行了巨大的工作。但是,在單個測試代碼中鞏固所有診斷可以幫助您達到國家腎基金會的指南12.和美國糖尿病協會13.用於監控和管理腎髒狀態。

Quest Diagnostics能夠與我們的高級CKD管理綜合麵板進行簡單的方法。單碼麵板評估:

  • 空腹水平
  • 空腹葡萄糖
  • HBA1C.
  • 肝功能(白蛋白,總和直接膽紅素,堿性磷酸酶,總蛋白,ALT,AST)
  • 尿白蛋白排泄(阿聯酋)
  • 血清肌酐/ EGFR

了解有關糖尿病和推進CKD管理麵板的更多信息


\r\nThe power of Quest
\r\n\r\n"}}" id="text-e2ccc6fd0a" class="cmp-text">


任務的力量

此信息僅供參與信息,並非作為醫療建議。醫生的考試選擇和解釋,診斷和患者管理決策應基於他/她的教育,臨床專業知識和患者的評估。

參考

1. CDC。慢性腎病在美國,2021年。更新了3月4日,2021年3月4日。2021年4月2日。https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html.

2. Vassalotti Ja,Devinney R,Lukasik S等人。CKD質量改進幹預PCMH集成:衛生計劃結果。我是J Manag Care。2019; 25(11):E326-E333。

3. Molnar Ao,Hiremath S,Brown Pa等。無計劃和崩潰透析的危險因素啟動:係統審查和薈萃分析的議定書。SYST REV.。2016; 5:117。DOI:10.1186 / s13643-016-0297-2

4. Lamarche B,Tchernof A,Moorjani S等人。小,致密的低密度脂蛋白顆粒作為男性缺血性心髒病風險的預測因子。Québec心血管研究的前瞻性結果。循環。1997年; 95(1):69-75。DOI:10.1161 / 01.CIR.95.1.69

5.國家膽固醇教育小組。國家膽固醇教育計劃(NCEP)專家小組的第三次報告檢測,評估和治療成人高血壓膽固醇(成人處理小組III)的最終報告。循環。2002; 106(25):3143-3421。

6. Davidson MH,Corson Ma,Alberts MJ等。共識組建議將脂蛋白相關的磷脂酶A2測試摻入心血管疾病風險評估指南。我是J心紅麻。2008; 101(12A):51F-57F。DOI:10.1016 / J.AMJCARD.2008.04.019

7. Fox CS,Sullivan L,D'Agostino R等。糖尿病持續時間對冠心病死亡率的顯著影響:Framingham心髒研究。糖尿病護理。2004; 27(3):704-708。DOI:10.2337 / DIACARE.27.3.704

8. Penn Ms,Klemes Ab。識別和記錄心血管風險減輕措施的多馬思。未來的心肺。2013; 9(4):497-506。DOI:10.2217 / FCA.13.27

9. Ikonomidis I,Mihalakeas Ca,萊卡斯j等。心血管風險預測中的多點方法。分析標記。2009; 26(5-6):273-285。DOI:10.3233 / DMA-2009-0633

10. Richard J,Lingvay I.肝髒脂肪變性和2型糖尿病:當前和未來的治療考慮。專家Rev Cardiovasc Ther。2011;9(3):321-328。DOI:10.1586 / ERC.11.15

11.國家腎髒基金會。腎病篩查的快速參考指南。4月2日,2021年4月2日。https://www.kidney.org/kidneydisease/siemens_hcp_quickreference ##

12. Levey As,Coresh J,Balk E等人。國家腎髒基礎實踐慢性腎病實踐指南:評價,分類和分層。安實習生。2003; 139(2):137-147。DOI:10.7326 / 0003-4819-139-2-200307150- 013

13.馬拉地素pH,高清,關閉KL。美國糖尿病協會糖尿病患者醫療標準2017。糖尿病護理。2017年;糖尿病 - 2017年醫療保健標準。糖尿病護理。2017; 40(SOPL 1):S1-S2。DOI:10.2337 / DC17-S001

在Covid-19健康危機期間,比以往任何時候都更快速行動和信任信息。

找出正在發生的事情

了解更多

慢性腎病

Baidu
map